Redica Systems
  • Login
  • Request a Demo
  • Use Cases
    • Redica Systems Pharma Intelligence
    • Redica Systems MedTech Intelligence
    • Request a Demo
  • Catalyst
  • Company
    • About Us
    • People
    • Careers
    • Press
  • Resources
    • Blog
    • Assessments
    • Reports
    • Webinars
    • Glossary
Redica Systems
    • Redica Systems Pharma Intelligence
    • Redica Systems MedTech Intelligence
    • Request a Demo
  • Catalyst
    • About Us
    • People
    • Careers
    • Press
    • Blog
    • Assessments
    • Reports
    • Webinars
    • Glossary
  • Login
  • Request a Demo

Resources

ProPublica | December 12, 2024

This article covers Glenmark Pharmaceuticals, an Indian drug manufacturer, which has issued seven recalls within a year for medications that failed to dissolve properly, a defect that can lead to serious health risks, including death. The following is a snip from the article: “To determine that the recalled Glenmark drugs were all made at […]

Webinar – Pharma Quality Inspection and Enforcement Trends in Japan

Tianish Laboratories Private Limited: A Timeline of Regulatory Assessments

Tianish Laboratories Private Limited (formerly known as Mylan Drugs India Pvt. Ltd) identified as a API (Active Pharmaceutical Ingredients) manufacturer. The FDA has inspected multiple sites associated with Tianish Laboratories Private Limited. This page documents the most recent 5 inspection documents associated with the HYDERABAD TELANGANA site, where the last known inspection was on 08 […]

KVK-Tech Warning Letters: A Timeline of Regulatory Assessments

FDA issued KVK-Tech, Inc (Newtown, PA) a Warning Letter on October 8, 2020, based on the outcome of an inspection ending March 13, 2020 (Link to the corresponding FDA 483). Additionally, the firm had also received a Warning Letter on February 11, 2020, based on the outcome of an inspection ending April 16, 2019 (Link […]

Webinar – Proactive vs. Reactive Quality: Building a Business Case for Quality Investments

Webinar – Make MedTech Postmarket Intelligence Work for You

Webinar – Calculating the Cost of Quality for Life Sciences: Perspective From a Former FDA Investigator

Report – Analysis of FDA 483 issued to Cipla Limited

Report – Analysis of FDA 483 issued to Jiangsu Hengrui Pharmaceuticals

Report – Aurobindo’s Quality Problems: A Timeline of Regulatory Actions and Recalls

« Older Entries
Newer Entries »
Company
  • About Redica Systems
  • People
  • Careers
  • Press
  • Contact Us
Catalyst
  • Redica Catalyst
  • Redica ID
  • Enrichment
  • Knowledge Graph
  • Redica Ontologies
Use Cases
  • For Pharma
  • For MedTech
  • Inspection Preparation
  • Vendor Quality
  • Regulatory Surveillance
Resources
  • Assessments
  • Reports
  • Webinars
  • Document Store
  • Blog
  • Glossary

© 2025 Redica. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
  • Status